



Client Performance Report

Sample Client
Q1 2026

One complete view of your pharmacy benefit.



Executive Summary

Plan performance at a glance, key trends and priority actions



Financial Performance

Gross and net cost, PMPM, top drugs by cost and high-cost claimants



Utilization Metrics

Demographics, prescriber patterns, utilization by condition and top pharmacies



Contract Review

Reconciliation, performance guarantees, call center and CAA readiness



Therapeutic Class Review & Top Conditions

GLP-1s, diabetes, autoimmune, HIV, migraine, cancer and mental health



Cost Containment & Clinical Management

Clinical case reviews, prior authorization, PBM programs and pipeline impact



Observations & Recommendations

Independent findings with prioritized, actionable next steps



Delivered quarterly

Independent, fiduciary-aligned analysis built from your claims data and PBM contract terms



SAMPLE REPORTS

Inside the Client Reporting Package

A selection of illustrative reports from our quarterly client reporting package, highlighting the depth of analysis and insights provided.

All figures are modeled as a sample employer plan with 2,850 members, 12 months of claims and do not represent any specific client's data.

IN THIS SECTION

Pharmacy Cost & Utilization Overview

Top Drugs & Therapeutic Classes

High-Cost Therapy Impact

Specialty Pharmacy Analysis

Autoimmune & Inflammatory Therapies

Clinical Value & Therapy Optimization

Comorbidity & Member Utilization

GLPs: Cost, Utilization & Trend

Cost Containment Opportunities

Pharmacy Network Analysis

CAA Readiness & PBM Oversight

Performance & Strategic Insights

Pharmacy Claims Cost Overview

Sample Employer Plan



TOTAL GROSS RX SPEND

\$4.22M

12 months ending March 2026. \$3.72M plan paid after member cost share.



GROSS COST PMPM

\$123.35

Per member per month across 2,850 members (34,200 member months)



GLP-1 SHARE

31.6%

\$1.33M across 176 utilizers



GENERIC RATE

86.4%

Generic dispensing rate by claim count




SPECIALTY SHARE

17.6%

\$742.5K from 34 members (1.2% of members)

Where the gross spend goes

Share of \$4.22M gross spend by therapy type



- **GLP-1s**
\$1.33M | 31.6%
- **Specialty**
\$742.5K | 17.6%
- **HIV antivirals**
\$418.9K | 9.9%
- **Other brands**
\$1.21M | 28.6%
- **Generics**
\$517.2K | 12.3%

Brands 87.7% (\$3.70M)

Generics 12.3% (\$517.2K)



Generics fill 86.4% of prescriptions but only 12.3% of spend.

Utilization Overview

Sample Employer Plan



GROSS RX SPEND

\$4,218,640

Ingredient cost, dispensing fees and tax, before rebates



MEMBER COST SHARE

\$497,799

Copays and deductibles, 11.8% of gross



NET PLAN PAID

\$3,720,841

88.2% of gross after member cost share



PRESCRIPTIONS

27,915

9.8 scripts per member per year

Cost metrics

Metric	Value
Members / Employees	2,850 / 2,140
Gross cost PMPM	\$123.35
Net plan cost PMPM	\$108.80
Gross cost per prescription	\$151.12
Member cost share	11.8%

Dispensing mix

Metric	Value
Generic dispensing rate (GDR)	86.4%
Brand share of gross spend	87.7% (\$3.70M)
Brand / generic cost per Rx	\$975 / \$21
Specialty share of gross spend	17.6% (\$742,516)
Mail / home delivery scripts	548 (2.0%)



Spend is highly concentrated: 1,612 claims over \$1,000 (5.8% of scripts) drive 70.4% of gross cost. The top 10 drugs account for 51.0% and the top 25 for 64.8%.

Top Drugs by Gross Spend

Sample Employer Plan

Rank	Drug	Category	Rx	Gross Spend	% of Gross	Cost / Rx	Relative spend
1	Zepbound	GLP-1	402	\$434,562	10.3%	\$1,081	
2	Mounjaro	GLP-1	368	\$395,232	9.4%	\$1,074	
3	Biktarvy	HIV	74	\$304,288	7.2%	\$4,112	
4	Ozempic	GLP-1	231	\$228,228	5.4%	\$988	
5	Wegovy	GLP-1	141	\$187,812	4.5%	\$1,332	
6	Dupixent Pen	Specialty	36	\$140,472	3.3%	\$3,902	
7	Humira (CF) Pen	Specialty	19	\$130,055	3.1%	\$6,845	
8	Skyrizi Pen	Specialty	5	\$114,800	2.7%	\$22,960	
9	Jardiance	Brand	214	\$112,136	2.7%	\$524	
10	Tremfya Pen	Specialty	7	\$104,160	2.5%	\$14,880	
11	Eliquis	Brand	136	\$67,592	1.6%	\$497	
12	Tezspire	Specialty	12	\$57,780	1.4%	\$4,815	
13	Trulicity	GLP-1	58	\$56,782	1.3%	\$979	
14	Cosentyx UnoReady Pen	Specialty	6	\$51,540	1.2%	\$8,590	
15	Descovy	HIV	22	\$47,388	1.1%	\$2,154	
Top 15 total			1,731	\$2,432,827	57.7%	\$1,405	

Category: GLP-1 Specialty HIV Other brand



TOP FIVE SPOTS

4 of 5

GLP-1 therapies hold four of the five highest-spend positions.



OF GROSS SPEND

57.7%

Concentrated in these 15 drugs, every one of them a brand.



OF PRESCRIPTIONS

6.2%

The same 15 drugs fill 1,731 of 27,915 scripts.

Top 25 Drugs by Utilization

Sample Employer Plan

#	Drug	Type	Rx	Users	Gross Cost	% Spend	Plan Paid
1	Zepbound	Traditional	402	56	\$434,562	10.3%	\$417,180
2	Atorvastatin Calcium	Traditional	396	86	\$3,881	0.1%	\$2,484
3	Mounjaro	Traditional	368	49	\$395,232	9.4%	\$379,423
4	Levothyroxine Sodium	Traditional	352	78	\$4,998	0.1%	\$3,199
5	Amoxicillin	Traditional	341	304	\$1,398	0.0%	\$895
6	Lisinopril	Traditional	318	72	\$1,558	0.0%	\$997
7	Amlodipine Besylate	Traditional	305	68	\$1,403	0.0%	\$898
8	Sertraline HCl	Traditional	287	68	\$2,497	0.1%	\$1,598
9	Rosuvastatin Calcium	Traditional	276	60	\$3,284	0.1%	\$2,102
10	Metformin HCl ER	Traditional	269	63	\$3,605	0.1%	\$2,307
11	Losartan Potassium	Traditional	254	56	\$2,438	0.1%	\$1,560
12	Escitalopram Oxalate	Traditional	238	58	\$1,928	0.0%	\$1,234
13	Ozempic	Traditional	231	34	\$228,228	5.4%	\$219,099

#	Drug	Type	Rx	Users	Gross Cost	% Spend	Plan Paid
14	Omeprazole	Traditional	226	63	\$1,627	0.0%	\$1,041
15	Bupropion XL	Traditional	219	55	\$5,804	0.1%	\$3,715
16	Jardiance	Traditional	214	21	\$112,136	2.7%	\$96,437
17	Albuterol Sulfate HFA	Traditional	207	80	\$5,879	0.1%	\$3,763
18	Gabapentin	Traditional	198	60	\$2,435	0.1%	\$1,558
19	Amoxicillin-Clavulanate	Traditional	187	170	\$2,169	0.1%	\$1,388
20	Prednisone	Traditional	181	151	\$706	0.0%	\$452
21	Fluoxetine HCl	Traditional	172	43	\$1,273	0.0%	\$815
22	Montelukast Sodium	Traditional	166	40	\$1,461	0.0%	\$935
23	Trazodone HCl	Traditional	158	41	\$964	0.0%	\$617
24	Hydrochlorothiazide	Traditional	151	33	\$634	0.0%	\$406
25	Metoprolol Succ ER	Traditional	147	33	\$1,573	0.0%	\$1,007




ANALYST NOTES The highest-volume drugs are low-cost generics, which is what a well-managed book looks like. The exceptions are GLP-1s: Zepbound and Mounjaro rank #1 and #3 by volume and carry 19.7% of gross spend between them. No action needed on the generic tail.

Top Therapeutic Classes

Sample Employer Plan

Gross spend by therapeutic class

Top 10 classes, ranked by gross spend



49.9%

TOP 3 CLASSES

Diabetes, weight management and HIV drive 49.9% of gross spend on just 13.3% of prescriptions. Cardiometabolic therapy is the single largest lever available to the plan.

Volume and representative drugs

#	Rx	% Gross	Representative drugs
1	2,712	24.8%	Mounjaro, Ozempic, Jardiance, Trulicity
2	671	15.1%	Zepbound, Wegovy, Qsymia
3	331	9.9%	Biktarvy, Descovy, Genvoya
4	512	6.2%	Dupixent, Tezspire, Linzess
5	745	5.3%	Humira, Enbrel, Amjevita
6	281	4.7%	Tremfya, Shingrix
7	126	4.5%	Skyrizi, Cosentyx, Zoryve
8	718	2.4%	Trelegy, Breztri, Symbicort
9	482	2.3%	Eliquis, Xarelto, Clopidogrel
10	224	2.2%	Ubrelvy, Qulipta, Emgality

High-Cost Therapies Drive the Economics

Sample Employer Plan



OF GROSS SPEND

59.1%

\$2.49M across specialty, HIV and GLP-1 therapies



SPECIALTY MEMBERS

34

1.2% of members; 124 specialty scripts (0.4% of all Rx)



HIV CLASS

\$418.9K

9.9% of gross spend across 29 members

Share of \$4.22M gross spend



Top specialty and HIV drugs by spend

Drug	Indication	Mbrs	Rx	Spend
Biktarvy	HIV	13	74	\$304,288
Dupixent Pen	Atopic dermatitis / asthma	5	36	\$140,472
Humira (CF) Pen	RA / Crohn's	3	19	\$130,055
Skyrizi Pen	Psoriasis / Crohn's	2	5	\$114,800
Tremfya Pen	Psoriasis / PsA	2	7	\$104,160
Tezspire	Severe asthma	2	12	\$57,780

Spend by therapy category

Category	Mbrs	Rx	Spend	% of Gross
Autoimmune / immunology	22	84	\$581,204	13.8%
Oncology	3	14	\$88,430	2.1%
Other specialty	9	26	\$72,882	1.7%
HIV antiretrovirals	29	331	\$418,905	9.9%
GLP-1 (diabetes + weight)	176	1,231	\$1,333,337	31.6%
High-cost total		1,686	\$2,494,758	59.1%

PBMs classify HIV antiretrovirals and Dupixent differently (specialty vs. non-specialty); HIV is shown separately here. Members may appear in more than one category.

Specialty Pharmacy Costs

Sample Employer Plan



SPECIALTY GROSS SPEND

\$742,516

17.6% of gross spend on 0.4% of prescriptions



SPECIALTY PRESCRIPTIONS

124

\$5,988 average gross cost per specialty script



IMMUNOLOGY SHARE

89.3%

Of the \$638,833 in specialty drugs listed at right

Top specialty drugs by gross spend

Excludes HIV antiretrovirals and GLP-1s

Specialty Drug	Therapeutic Area	Rx	Gross Spend	Cost / Rx
Dupixent Pen	Immunology / atopic dermatitis	36	\$140,472	\$3,902
Humira (CF) Pen	Immunology	19	\$130,055	\$6,845
Skyrizi Pen	Immunology / psoriasis	5	\$114,800	\$22,960
Tremfya Pen	Immunology / psoriasis	7	\$104,160	\$14,880
Tezspire	Severe asthma	12	\$57,780	\$4,815
Cosentyx UnoReady Pen	Immunology	6	\$51,540	\$8,590
Enbrel SureClick	Immunology	2	\$17,024	\$8,512
Amjevita (biosimilar)	Immunology	1	\$12,730	\$12,730
Spravato	Treatment-resistant depression	8	\$10,272	\$1,284
Top 9 shown (86.0% of specialty)		96	\$638,833	\$6,655



Immunology is 89.3% of the listed specialty spend. Biosimilar conversion is an immediate opportunity.

Autoimmune & Inflammatory

Sample Employer Plan

By category

48 members; \$642,168 gross, 15.2% of all drug spend

Category	Users	Rx	Gross Cost	% of Spend	Generic Rate
Biologic & targeted (RA, psoriasis, IBD)	17	48	\$440,732	10.4%	0.0%
Multiple sclerosis	0	0	\$0	0.0%	-
Conventional DMARD & IBD	24	71	\$3,184	0.1%	100.0%
Type 2 inflammatory (atopic dermatitis, asthma)	7	48	\$198,252	4.7%	0.0%
Total	48	167	\$642,168	15.2%	42.5%

Users may appear in more than one category. Not counted on purpose: methotrexate generic tablets (also used in cancer), prednisone and other systemic steroids (many uses).

Top autoimmune & inflammatory drugs by cost

#	Drug	Rx	Users	Gross Cost	% of Spend
1	Dupixent Pen	36	5	\$140,472	3.3%
2	Humira (CF) Pen	19	3	\$130,055	3.1%
3	Skyrizi Pen	5	2	\$114,800	2.7%
4	Tremfya Pen	7	2	\$104,160	2.5%
5	Tezspire	12	2	\$57,780	1.4%
6	Cosentyx UnoReady Pen	6	2	\$51,540	1.2%
7	Enbrel SureClick	2	1	\$17,024	0.4%
8	Amjevita (biosimilar)	1	1	\$12,730	0.3%
9	Otezla	3	1	\$8,853	0.2%



ANALYST NOTES A small number of members on biologic and targeted therapy drive 10.4% of total drug spend.

Comorbidity & Member Utilization Patterns

Sample Employer Plan

Members in both condition groups

Diagonal is the group total; each other cell is members in both groups

Condition	Diabetes	Mental health	Autoimmune	Migraine	Cancer	HIV
Diabetes	312	85	6	5	7	3
Mental health	85	526	14	22	12	8
Autoimmune	6	14	48	2	1	0
Migraine	5	22	2	57	0	0
Cancer	7	12	1	0	31	0
HIV	3	8	0	0	0	29

Spend concentration

Utilizers	Members	Share of Plan Paid
Top 1% of utilizers	22	38.6%
Top 5% of utilizers	110	67.9%
Top 10% of utilizers	220	82.4%
Top 20% of utilizers	439	93.1%

Members by number of condition groups

Groups	Members	% Mbrs	Plan Paid	% Paid	Per Mbr
None of these	1,338	60.9%	\$481,650	12.9%	\$360
One	731	33.3%	\$2,108,344	56.7%	\$2,884
Two	111	5.1%	\$781,905	21.0%	\$7,044
Three or more	16	0.7%	\$348,942	9.4%	\$21,809
Total utilizers	2,196	100.0%	\$3,720,841	100.0%	\$1,694

Condition groups: diabetes, mental health, autoimmune and inflammatory, migraine, cancer, HIV. Plan paid covers all of each member's therapy, not only the condition drugs.



47 members

exceeded \$10,000 in plan paid during the period



ANALYST NOTES The top 1% of utilizers account for 38.6% of plan paid, and members in three or more condition groups average \$21,809 each.

GLP-1s: A Significant Cost Driver

Sample Employer Plan



GLP-1 GROSS SPEND

\$1.33M

31.6% of gross spend, April 2025 to March 2026



UTILIZERS

176

6.2% of members; \$7,576 average annual gross cost each



IN TWO DRUGS

62.2%

Zepbound and Mounjaro total \$829.8K of the class

GLP-1 detail by drug

Drug	Primary Use	Utilizers	Rx	Gross Spend	Cost / Utilizer	% of Gross
Zepbound	Weight management	56	402	\$434,562	\$7,760	10.3%
Mounjaro	Type 2 diabetes	49	368	\$395,232	\$8,066	9.4%
Ozempic	Type 2 diabetes	34	231	\$228,228	\$6,713	5.4%
Wegovy	Weight management	22	141	\$187,812	\$8,537	4.5%
Trulicity	Type 2 diabetes	9	58	\$56,782	\$6,309	1.3%
Rybelsus	Type 2 diabetes	6	31	\$30,721	\$5,120	0.7%
GLP-1 class total		176	1,231	\$1,333,337	\$7,576	31.6%

Utilizers are counted once, under their most recent GLP-1 therapy.

Spend by indication



● Type 2 diabetes
53.3%

● Weight management
46.7%


\$711.0K diabetes and \$622.4K weight management, totaling \$1,333,337.

GLP-1 Trend

Sample Employer Plan

Monthly GLP-1 gross spend

April 2025 to March 2026 | 12-month total \$1,333,337



Weight-management GLP-1s (Zepbound and Wegovy) are 46.7% of GLP-1 spend. Coverage is legend-only with prior authorization and spend is still growing about 17% quarter over quarter.



GLP-1 PRESCRIPTIONS

1,231

4.4% of all prescriptions; \$1,083 average cost per script



MONTHLY SPEND GROWTH

+104%

From \$74.1K (Apr 2025) to \$151.2K (Mar 2026)



WEIGHT MANAGEMENT

46.7%

\$622.4K of GLP-1 spend in Zepbound and Wegovy

Cost Plus Drugs (MCCPD)

Sample Employer Plan



PLAN SAVINGS / YR

\$78.3K

1,842 claims priced below the current plan cost



MEMBER SAVINGS / YR

\$17.9K

Out-of-pocket reduction on cash-pay-eligible fills



OF CLAIMS MATCHED

6.6%

Cost Plus carries ~2,370 generics; a targeted channel

Savings by channel

Channel	Claims	Plan Savings	% Cheaper
Retail	1,583	\$53,910	61%
Mail order	259	\$24,382	74%
Total	1,842	\$78,292	

Share of plan savings

Retail 68.9%	Mail 31.1%
---------------------	-------------------

Top five reroute drugs

Drug	Condition Treated	Rx	Plan Savings
Atomoxetine HCl 25mg	ADHD	9	\$4,712
Fidaxomicin 200mg	C. difficile infection	1	\$2,618
Icosapent ethyl 0.5g	High triglycerides	4	\$2,540
Bupropion XL 300mg	Depression	41	\$2,105
Albuterol HFA	Asthma / COPD	118	\$1,934
Top five total (17.8% of savings)		173	\$13,909

Pharmacy Utilization & Network

Sample Employer Plan

By channel

412 pharmacies filled claims; 1 out-of-network claim totaling \$38

Channel	Rx	Members	Gross Cost	% of Spend	Generic Rate
Retail	27,055	2,154	\$2,744,800	65.1%	87.6%
Mail	548	118	\$350,120	8.3%	71.9%
Specialty	312	47	\$1,123,720	26.6%	5.1%
Total	27,915		\$4,218,640	100.0%	86.4%

Days supply mix by channel (share of Rx)

Channel	30 Days or Less	35 to 83 Days	84 Days or More
Retail	74%	2%	24%
Mail	31%	3%	66%
Specialty	93%	4%	3%

By pharmacy group

Pharmacy Group	Locations	Rx	Gross Cost	% of Spend
PBM specialty pharmacy	3	296	\$1,071,480	25.4%
Walgreens	58	6,912	\$694,318	16.5%
CVS Pharmacy	64	6,340	\$662,905	15.7%
Other / independent	198	5,585	\$626,035	14.8%
PBM mail pharmacy	1	548	\$350,120	8.3%
Walmart	41	3,488	\$318,420	7.5%
Publix	22	2,406	\$265,112	6.3%
Kroger	18	1,544	\$162,880	3.9%
Costco	6	712	\$58,210	1.4%
Amazon Pharmacy	1	84	\$9,160	0.2%
Total	412	27,915	\$4,218,640	100.0%

Chains grouped by name. Specialty channel counts claims flagged specialty, wherever filled.

CAA Readiness & PBM Progress

Sample Employer Plan

Consolidated Appropriations Act obligations that touch the pharmacy benefit, and where the plan and PBM stand on each.

Requirement	What It Covers	Status / Next Step
Prescription Drug Data Collection (RxDC) Reporting	Annual plan-level report of pharmacy and medical costs to the Departments, due June 1; usually filed by the PBM and carrier on the plan's behalf.	Confirm the 2025 reference-year filing was made, and a copy is on file.
Gag Clause Prohibition Compliance Attestation	Annual attestation that no service-provider contract restricts the plan's access to cost and quality data, due December 31.	Confirm the 2025 attestation was filed, and the PBM contract has no restrictive terms.
Broker & Consultant Compensation Disclosure	Disclosure of direct and indirect compensation from covered service providers under ERISA 408(b)(2) as amended by the CAA.	Confirm disclosures are on file from every covered service provider.
Plan Data Access & Audit Rights	Contract terms giving the plan claim-level data and audit rights needed for fiduciary oversight of the PBM.	Confirm against the current PBM contract.
PBM Transparency & Progress	What the PBM currently reports on rebates, fees and spread, and its plan for new federal PBM reporting requirements.	Request the PBM's current transparency reports and readiness update.



ANALYST NOTES Each item needs a document or attestation on file rather than analysis. Confirm with the plan sponsor and the PBM which filings are complete and add the PBM's written progress update to the next review. This page is compliance tracking, not legal advice.

Reconciliation: Discount Guarantees

Sample Employer Plan – Illustrative

TeliosRx independent calculation of achieved AWP discounts

Guarantees measured on ingredient cost against AWP

Channel	Drug Type	Claims	Ingredient Cost Paid	Total AWP	TeliosRx Achieved	Guaranteed	TeliosRx Over / (Under)	PBM Achieved	PBM Over / (Under)
Mail Order	Brand	512	\$1,704,320	\$2,219,745	23.22%	24.00%	(\$17,314.01)	Not reconciled	N/A
Mail Order	Generic	2,364	\$214,124	\$1,652,191	87.04%	88.00%	(\$15,861.04)	Not reconciled	N/A
Retail 30	Brand	11,180	\$7,730,078	\$9,509,261	18.71%	19.25%	(\$51,350.01)	18.69%	(\$53,251.86)
Retail 30	Generic	96,455	\$1,614,496	\$10,524,745	84.66%	87.00%	(\$246,279.04)	84.79%	(\$232,596.87)
Retail 90	Brand	5,930	\$3,727,179	\$4,752,842	21.58%	22.50%	(\$43,726.14)	21.54%	(\$45,627.28)
Retail 90	Generic	21,640	\$650,364	\$6,338,830	89.74%	88.50%	\$78,601.50	89.81%	\$83,038.68
Specialty	All	1,584	\$5,528,400	\$7,074,994	21.86%	23.50%	(\$116,029.90)	21.83%	(\$118,152.40)
Total		139,665	\$21,168,961	\$42,072,608			(\$411,958.64)		(\$366,589.73)



ANALYST NOTES Six of the seven channels landed under the contracted discount, a \$411,959 shortfall for the year. The PBM's own reconciliation left mail order out entirely and reports a smaller gap.

Reconciliation: Dispensing Fees

Sample Employer Plan – Illustrative

TeliosRx independent dispensing fee reconciliation

Average fee per claim against the contracted maximum

Channel	Drug Type	Claims	Total Dispensing Fees	TeliosRx Avg Fee	Guaranteed Fee	TeliosRx Over / (Under)	PBM Avg Fee	PBM Over / (Under)
Mail Order	Brand	512	-	-	-	-	Not reconciled	N/A
Mail Order	Generic	2,364	-	-	-	-	Not reconciled	N/A
Retail 30	Brand	11,180	\$12,521.60	\$1.12	\$0.90	(\$2,459.60)	\$1.10	(\$2,236.00)
Retail 30	Generic	96,455	\$98,384.10	\$1.02	\$0.75	(\$26,042.85)	\$1.00	(\$24,113.75)
Retail 90	Brand	5,930	\$15,121.50	\$2.55	\$2.15	(\$2,372.00)	\$2.53	(\$2,253.40)
Retail 90	Generic	21,640	\$51,936.00	\$2.40	\$1.90	(\$10,820.00)	\$2.38	(\$10,387.20)
Specialty	All	1,584	-	-	-	-	Not reconciled	N/A
Total		139,665	\$177,963.20			(\$41,694.45)		(\$38,990.35)

Mail order and specialty carry no dispensing fee under this contract, and the PBM did not reconcile those channels.



ANALYST NOTES Every retail line paid above the contracted maximum fee, \$41,694 over the year on 135,205 retail claims.

Reconciliation: Rebate Guarantees

Sample Employer Plan - Illustrative

TeliosRx independent rebate guarantee reconciliation

Minimum guaranteed rebate by eligible brand claim

Channel	Total Claims	Rebate Excluded	TeliosRx Eligible	\$ / Rx Guarantee	TeliosRx Min Guaranteed	PBM Eligible	PBM Min Guaranteed	Difference
Brand Retail 30 (RB30)	11,180	2,090	9,090	\$120	\$1,090,800	8,604	\$1,032,480	\$58,320
Brand Retail 90 (RB90)	5,930	470	5,460	\$260	\$1,419,600	5,246	\$1,363,960	\$55,640
Mail Brand	512	32	480	\$260	\$124,800	0	\$0	\$124,800
Specialty	1,584	121	1,463	\$1,000	\$1,463,000	1,224	\$1,224,000	\$239,000
Total	19,206	2,713	16,493		\$4,098,200	15,074	\$3,620,440	\$477,760

Difference is the TeliosRx minimum guaranteed rebate less the PBM calculation. The PBM treated mail brand claims as ineligible and applied a narrower eligible-claim definition on retail and specialty.



ANALYST NOTES The eligible-claim definition drives the gap: 16,493 eligible claims under the contract terms against 15,074 counted by the PBM, worth \$477,760 in minimum guaranteed rebates.



Thank You!

www.teliosrx.com

Follow us on [LinkedIn](#)

Engineering Smarter Pharmacy Benefits

Confidentiality & Use Notice

This document is strictly private, confidential, and proprietary to TeliosRx Consulting, LLC and is provided solely to the named recipient(s) for the evaluation of pharmacy benefit manager (PBM) proposals. It contains commercially sensitive financial terms, trade secret pricing, rebate structures, network arrangements, and program details proprietary to each named PBM vendor, together with TeliosRx's consulting work product and analyses.

This document in whole or in part, in any form may not be copied, printed, distributed, reproduced, summarized, posted, transmitted, or otherwise disclosed to any third party without the prior written consent of TeliosRx Consulting, LLC. Recipients agree to maintain its confidentiality and restrict use to the stated purpose.

The analyses, projections, rankings, and recommendations contained herein are based on information available at the time of preparation and are illustrative for decision-support purposes only. Actual results may vary based on utilization, drug mix, enrollment, contract negotiation outcomes, and other factors. TeliosRx Consulting, LLC makes no representation or warranty, express or implied, as to future financial performance.